Sector Insights

Which Dividend Stock Is Better: Energy Transfer or Enterprise Products?
Sector Insights Which Dividend Stock Is Better: Energy Transfer or Enterprise Products?

Investors seeking reliable dividend income often turn to the midstream energy sector, where companies like Energy Transfer and Enterprise Products Partners stand out. Both firms have a significant presence in North America, but deciding which one offers a better dividend stock can be a challenging

Jaguar Health Reports Q3 2024 Revenue Increase and Operational Progress
Sector Insights Jaguar Health Reports Q3 2024 Revenue Increase and Operational Progress

Jaguar Health has unveiled its financial results for the third quarter of 2024, indicating notable strides in growth and development. The announcement revealed a significant increase in net revenue and highlighted the company's continued advancement in its core programs, underscoring its resilience

Can Evaxion Biotech Overcome Nasdaq Delisting and Financial Strain?
Sector Insights Can Evaxion Biotech Overcome Nasdaq Delisting and Financial Strain?

Evaxion Biotech A/S, a clinical-stage biotech firm listed on Nasdaq under the ticker EVAX, is currently navigating a challenging landscape as it appeals a delisting determination from Nasdaq. This stems from non-compliance with the minimum stockholder equity requirement of $2.5 million stipulated

Volkswagen Invests $5.8 Billion in Rivian, Boosting EV Collaboration
Sector Insights Volkswagen Invests $5.8 Billion in Rivian, Boosting EV Collaboration

In an era where electric vehicles (EVs) are becoming the vanguard of the automotive industry, Volkswagen has taken a notable step by investing $5.8 billion in Rivian. This strategic partnership, formulated under their joint venture Rivian and VW Group Technology LLC, exemplifies a strong vote of

Can Amgen's MariTide Overcome Doubts to Lead Obesity Drug Market?
Sector Insights Can Amgen's MariTide Overcome Doubts to Lead Obesity Drug Market?

Shares of Amgen edged up in premarket trading after the firm's announcement that its experimental obesity drug, MariTide, does not negatively impact bone mineral density. This comes following a more than 7% plunge in stock due to a report by Cantor Fitzgerald analysts, which had cited data implying

UBS Faces Scrutiny Over Inherited Russian Clients After Credit Suisse Acquisition
Sector Insights UBS Faces Scrutiny Over Inherited Russian Clients After Credit Suisse Acquisition

In the world of high finance, the recent acquisition of Credit Suisse by UBS has stirred significant regulatory waters, mainly due to concerns over Russian clients tied to the ailing bank Credit Suisse. The U.S. Office of Foreign Assets Control (OFAC), a globally recognized authority on sanctions

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later